Meeting
2014 ASCO Annual Meeting
Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy.
Authors
Sarika Jain
Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT02038010
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS672)
DOI
10.1200/jco.2014.32.15_suppl.tps672
Abstract #
TPS672
Poster Bd #
126A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial.
First Author: Tejal Amar Patel
Poster
2011 ASCO Annual Meeting
Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer.
First Author: D. Gajria
Poster
2017 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.
First Author: Laura Spring
Poster
2016 ASCO Annual Meeting
Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.
First Author: Sarika Jain